A Randomized Phase III Trial Of Dabrafenib + Trametinib Followed By Ipilimumab + Nivolumab At Progression Vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression In Patients With Advanced Brafv600 Mutant Melanoma
Posted Date: May 23, 2016
- Investigator: Nagla Abdel Karim
- Specialties: Hematology Oncology, Oncology, Cancer, Skin Cancer
- Type of Study: Drug
This research study has two treatment regimens, with a potential to crossover from one to the other. Arm A will receive the study drugs ipilimumab and nivolumab first, and at time of disease progression will crossover to Arm C to receive the study drugs dabrafenib and trametinib. Arm B will receive the study drugs dabrafenib and trametinib first, and at time of disease progression will crossover to Arm D to receive the study drugs ipilimumab and nivolumab
Criteria:
To Be Eligible, Patients Must Have Been Diagnosed With Melanoma, A Type Of Skin Cancer, And The Melanoma Has Spread Beyond It's Local Area And Cannot Be Surgically Removed.
Keywords:
Skin Cancer, Melanoma, Cancer, Ea6134, Advanced Brafv600 Mutant
For More Information:
University Of Cincinnati Cancer Institute
513-584-7698
kastla@uc.edu